Department Team Catgegory: Cardiovascular Department

A Phase 3, randomised, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of Milvexian, an Oral Factor XIa Inhibitor, after a recent acute coronary syndrome. (LIBREXIA-ACS). “A Phase 3, randomised, double-blind, double-dummy, parallel group, active controlled study to evaluate the efficacy and safety of Milvexian, an Oral Factor Xla Inhibitor, versus Apixaban in…